546 related articles for article (PubMed ID: 25593051)
1. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry.
Hira RS; Kennedy K; Nambi V; Jneid H; Alam M; Basra SS; Ho PM; Deswal A; Ballantyne CM; Petersen LA; Virani SS
J Am Coll Cardiol; 2015 Jan; 65(2):111-21. PubMed ID: 25593051
[TBL] [Abstract][Full Text] [Related]
2. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
Morimoto T; Fukui T; Lee TH; Matsui K
Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
[TBL] [Abstract][Full Text] [Related]
3. Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention: a population-based, nested case-control study.
Lin KJ; De Caterina R; García Rodríguez LA
Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):70-7. PubMed ID: 24254886
[TBL] [Abstract][Full Text] [Related]
4. Potential Impact of the 2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease Recommendations on the Inappropriate Routine Use of Aspirin and Aspirin Use Without a Recommended Indication for Primary Prevention of Cardiovascular Disease in Cardiology Practices: Insights From the NCDR PINNACLE Registry.
Hira RS; Gosch KL; Kazi DS; Yeh RW; Kataruka A; Maddox TM; Shah T; Jneid H; Bhatt DL; Virani SS
Circ Cardiovasc Qual Outcomes; 2022 Mar; 15(3):e007979. PubMed ID: 35098732
[TBL] [Abstract][Full Text] [Related]
5. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.
Dehmer SP; Maciosek MV; Flottemesch TJ; LaFrance AB; Whitlock EP
Ann Intern Med; 2016 Jun; 164(12):777-86. PubMed ID: 27064573
[TBL] [Abstract][Full Text] [Related]
6. Aspirin for primary prevention: yes or no?
Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
[TBL] [Abstract][Full Text] [Related]
7. A national survey on aspirin patterns of use and persistence in community outpatients in Italy.
Filippi A; Bianchi C; Parazzini F; Cricelli C; Sessa E; Mazzaglia G
Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):695-703. PubMed ID: 21450601
[TBL] [Abstract][Full Text] [Related]
8. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women.
van Kruijsdijk RC; Visseren FL; Ridker PM; Dorresteijn JA; Buring JE; van der Graaf Y; Cook NR
Heart; 2015 Mar; 101(5):369-76. PubMed ID: 25475110
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
Shiffman D; Slawsky K; Fusfeld L; Devlin JJ; Goss TF
Clin Ther; 2012 Jun; 34(6):1387-94. PubMed ID: 22560621
[TBL] [Abstract][Full Text] [Related]
10. Aspirin for primary prevention of cardiovascular disease events.
Nemerovski CW; Salinitri FD; Morbitzer KA; Moser LR
Pharmacotherapy; 2012 Nov; 32(11):1020-35. PubMed ID: 23019080
[TBL] [Abstract][Full Text] [Related]
11. Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment.
Mora S; Manson JE
JAMA Intern Med; 2016 Aug; 176(8):1195-204. PubMed ID: 27322595
[TBL] [Abstract][Full Text] [Related]
12. Aspirin overprescription in primary cardiovascular prevention.
Manes C; Giacci L; Sciartilli A; D'Alleva A; De Caterina R
Thromb Res; 2006; 118(4):471-7. PubMed ID: 16321425
[TBL] [Abstract][Full Text] [Related]
13. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
Wolff T; Miller T; Ko S
Ann Intern Med; 2009 Mar; 150(6):405-10. PubMed ID: 19293073
[TBL] [Abstract][Full Text] [Related]
14. Annual Risk of Major Bleeding Among Persons Without Cardiovascular Disease Not Receiving Antiplatelet Therapy.
Selak V; Kerr A; Poppe K; Wu B; Harwood M; Grey C; Jackson R; Wells S
JAMA; 2018 Jun; 319(24):2507-2520. PubMed ID: 29946729
[TBL] [Abstract][Full Text] [Related]
15. Aspirin for primary prevention: do potential benefits outweigh the risks?
Shakib S
Intern Med J; 2009 Jun; 39(6):401-7. PubMed ID: 19580619
[TBL] [Abstract][Full Text] [Related]
16. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force.
Whitlock EP; Burda BU; Williams SB; Guirguis-Blake JM; Evans CV
Ann Intern Med; 2016 Jun; 164(12):826-35. PubMed ID: 27064261
[TBL] [Abstract][Full Text] [Related]
17. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Bibbins-Domingo K;
Ann Intern Med; 2016 Jun; 164(12):836-45. PubMed ID: 27064677
[TBL] [Abstract][Full Text] [Related]
18. The role of the cardiologist in the primary prevention of cardiovascular disease with aspirin.
Verheugt FW
J Am Coll Cardiol; 2015 Jan; 65(2):122-4. PubMed ID: 25593052
[No Abstract] [Full Text] [Related]
19. Effects of changing guidelines on prescribing aspirin for primary prevention of cardiovascular events.
Hissett J; Folks B; Coombs L; Leblanc W; Pace WD
J Am Board Fam Med; 2014; 27(1):78-86. PubMed ID: 24390889
[TBL] [Abstract][Full Text] [Related]
20. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.
Hayden M; Pignone M; Phillips C; Mulrow C
Ann Intern Med; 2002 Jan; 136(2):161-72. PubMed ID: 11790072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
